Skip to main content
Premium Trial:

Request an Annual Quote

Sure, It's Risky, But...

In the third installment of an essay on the risks and advantages of open access publishing, Cameron Neylon talks about the social issues surrounding the movement at Science in the open. While it's "unreasonable to expect the rapid adoption of new web based tools and even more unreasonable to expect scientists to change their overall approach to their research en masse," he says that a number of legitimate factors contribute to a lot of scientists' hesitation to embrace open access. Perceived cost, the risk that someone could scoop their data, and "simple inertia" are all driving factors. Check out his first and second installments on why we need open access and issues around the tools for doing open science.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.